Trial
NCT06630325
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University; Eli Lilly and Company; AstraZeneca
Condition
Advanced Breast Carcinoma
Intervention
Abemaciclib
Why stopped
Loss of support.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-28